Stereotaxis (STXS)
:STXS
Want to see STXS full AI Analyst Report?
Top Page
Stereotaxis
(STXS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▼(-1.48% Downside)
Action:ReiteratedDate:04/16/26
The score is held back primarily by persistent losses and worsening free cash flow burn, despite improving revenue and solid gross margins. Near-term technicals are modestly supportive but longer-term trends remain weak. The latest earnings call guidance and product/manufacturing ramp plans improve the outlook, while the Robocath acquisition adds strategic upside alongside execution and financing/dilution risk.
Positive Factors
Regulatory approvals enabling US/EU commercialization
Securing U.S. and EU clearances for core systems and catheters removes major regulatory barriers, enabling direct commercialization across key markets. This provides a durable foundation to place systems, expand installed base, and drive recurring disposables and service revenue over the next several quarters.
Negative Factors
Persistent negative free cash flow and cash burn
Sustained negative operating and free cash flow is a structural constraint: ongoing cash burn forces reliance on external financing or equity issuance, compresses runway, and can dilute shareholders. Continued burn limits ability to invest in manufacturing scale or sustained commercialization without funding plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approvals enabling US/EU commercialization
Securing U.S. and EU clearances for core systems and catheters removes major regulatory barriers, enabling direct commercialization across key markets. This provides a durable foundation to place systems, expand installed base, and drive recurring disposables and service revenue over the next several quarters.
Read all positive factors
Stereotaxis (STXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$185.21M
Dividend YieldN/A
Average Volume (3M)583.61K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth20.28%
EPS Growth15.25%
CountryUS
Employees139
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.25
Shares Outstanding97,477,540
10 Day Avg. Volume380,338
30 Day Avg. Volume583,610
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue5.53
Enterprise Value/Gross Profit10.50
Enterprise Value/Ebitda-8.83
Forecast
1Y Price Target
$4.25Price Target Upside109.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$41.10M
Stereotaxis Business Overview & Revenue Model
Company Description
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesi...
How the Company Makes Money
Stereotaxis makes money primarily by selling and supporting its robotic magnetic navigation ecosystem used in hospital electrophysiology labs. Key revenue streams typically include: (1) Capital equipment sales: one-time (or milestone-based) revenu...
Stereotaxis Earnings Call Summary
Earnings Call Date:Mar 09, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call communicated substantial strategic and regulatory progress — including U.S./EU approvals for GenesisX, MAGiC and MAGiC Sweep, double-digit revenue growth and clear commercial and manufacturing ramp plans — while also acknowledging meaningful operational challenges: catheter manufacturing constraints, a sharp quarter-on-quarter recurring revenue decline, increased negative free cash flow and persistently low system gross margins. Management provided concrete remediation plans (manufacturing scale-up, Osypka ramp to ~500 catheters/month, Synchrony commercialization, and mixed capital/placement sales models) and positive 2026 guidance (> $40M revenue), signaling a constructive outlook if execution continues. Overall, the highlights (regulatory wins, revenue growth, margin improvement potential and clear go-to-market plans) outweigh the operational lowlights, but execution risk remains material.Positive Updates
Regulatory Approvals for Core Products
Achieved U.S. and European regulatory approvals for GenesisX robot, MAGiC Ablation Catheter and MAGiC Sweep mapping catheter — milestone regulatory wins establishing a foundation for EP commercialization and multi-product adoption.
Negative Updates
Catheter Manufacturing Constraints and Shortages
MAGiC catheter production has been constrained (dozens/month) versus target (hundreds/month); Q4 and early 2026 catheter shortages were caused by a production process change at contract manufacturer Osypka and slowed commercial supply and revenue.
Read all updates
Q4-2025 Updates
Positive
Negative
Regulatory Approvals for Core Products
Achieved U.S. and European regulatory approvals for GenesisX robot, MAGiC Ablation Catheter and MAGiC Sweep mapping catheter — milestone regulatory wins establishing a foundation for EP commercialization and multi-product adoption.
Read all positive updates
Company Guidance
Stereotaxis guided fiscal 2026 revenue to surpass $40 million (double‑digit growth year‑over‑year) with quarterly revenue below $10M in H1 and above $10M in H2, and plans to establish at least five active GenesisX programs while manufacturing roughly one GenesisX every two months at its St. Louis facility (scalable to several dozen/year); orders may outpace production. MAGiC catheter output is expected to ramp from ~100 units in March to ~500 catheters/month by year‑end (the catheter opportunity in existing robotic procedure volume is >$20M annually) and per‑procedure disposable revenue is rising from about $1,000 to over $5,000. Synchrony is expected to receive FDA clearance in the coming weeks with >$3M of initial 2026 revenue projected (capital pricing roughly $150k–$200k/system), recurring and system revenue should both grow through the year, and management expects recurring gross margin (67% in 2025) to exceed 75% and system gross margin (21% in 2025) to exceed 50% within ~3 years. Financial posture: FY2025 revenue was $32.4M (Q4 $8.6M), adjusted operating expenses $26.3M, adjusted operating loss $9.3M, adjusted net loss $8.8M, negative free cash flow $13.8M, cash $13.4M and no debt, with management expecting reduced cash use and stable operating expenses in 2026.Stereotaxis Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.38M | 26.92M | 26.77M | 28.15M | 35.02M |
| Gross Profit | 17.07M | 14.59M | 14.86M | 18.47M | 23.23M |
| EBITDA | -20.56M | -23.77M | -21.24M | -18.35M | -12.78M |
| Net Income | -21.64M | -24.05M | -20.71M | -18.29M | -10.72M |
Balance Sheet | |||||
| Total Assets | 52.25M | 46.72M | 41.91M | 53.41M | 60.98M |
| Cash, Cash Equivalents and Short-Term Investments | 13.42M | 12.22M | 19.82M | 28.43M | 38.74M |
| Total Debt | 5.44M | 6.01M | 5.49M | 5.86M | 6.11M |
| Total Liabilities | 33.53M | 35.29M | 19.99M | 21.48M | 21.56M |
| Stockholders Equity | 18.72M | 11.43M | 21.92M | 31.93M | 39.42M |
Cash Flow | |||||
| Free Cash Flow | -13.78M | -8.53M | -9.51M | -10.79M | -4.34M |
| Operating Cash Flow | -13.69M | -8.50M | -9.14M | -8.41M | -2.95M |
| Investing Cash Flow | -93.00K | 74.00K | 19.77M | -22.09M | -1.40M |
| Financing Cash Flow | 14.76M | 297.00K | 81.00K | 220.00K | 547.00K |
Stereotaxis Technical Analysis
Positive
2.03
Price Trends
1.98
Positive
2.21
Negative
2.45
Negative
Market Momentum
<0.01
Negative
57.30
Neutral
80.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 1.89, above the 50-day MA of 1.98, and below the 200-day MA of 2.45, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.30 is Neutral, neither overbought nor oversold. The STOCH value of 80.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 57 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $2.54B | 29.55 | 15.58% | 0.95% | 13.53% | 30.00% | |
65 Neutral | $3.70B | 25.02 | 8.52% | ― | 11.34% | 12.26% | |
62 Neutral | $1.46B | 270.11 | -2.43% | ― | 14.88% | 74.68% | |
52 Neutral | $1.35B | -15.97 | -23.24% | ― | -23.72% | -296.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $185.21M | -9.98 | -191.60% | ― | 20.28% | 15.25% | |
51 Neutral | $28.55M | -5.14 | -164.78% | ― | 3.99% | -17.45% |
* Healthcare Sector Average
STXS
Stereotaxis
1.90
-0.19
-9.09%
ATRC
Atricure
28.78
-1.53
-5.05%
LMAT
Lemaitre Vascular
111.53
30.67
37.93%
MMSI
Merit Medical Systems
62.01
-32.21
-34.19%
STAA
Staar Surgical
27.29
7.85
40.38%
MLSS
Milestone Scientific
0.35
-0.56
-61.10%
Stereotaxis Corporate Events
Business Operations and StrategyM&A Transactions
Stereotaxis to Acquire Robocath in Strategic Robotics Deal
Positive
Apr 15, 2026
On April 14, 2026, Stereotaxis agreed to acquire 100% of French robotic cardiology innovator Robocath in a deal expected to close in July 2026, subject to debt restructuring, French regulatory clearance, and other customary conditions. The upfront...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.